(Q42834569)

English

Biochemical and antiproliferative properties of 4-[ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor

scientific article published on October 1997

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 November 2017

Biochemical and antiproliferative properties of 4-[ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor (English)

1 reference

Europe PubMed Central

8 November 2017

1 reference

ChEBI release 2020-05-28

author name string

Fry DW

1

1 reference

Europe PubMed Central

8 November 2017

Nelson JM

2

1 reference

Europe PubMed Central

8 November 2017

Slintak V

3

1 reference

Europe PubMed Central

8 November 2017

Keller PR

4

1 reference

Europe PubMed Central

8 November 2017

Rewcastle GW

5

1 reference

Europe PubMed Central

8 November 2017

Denny WA

6

1 reference

Europe PubMed Central

8 November 2017

Zhou H

7

1 reference

Europe PubMed Central

8 November 2017

Bridges AJ

8

1 reference

Europe PubMed Central

8 November 2017

language of work or name

0 references

publication date

1 October 1997

1 reference

Europe PubMed Central

8 November 2017

Biochemical Pharmacology

1 reference

Europe PubMed Central

8 November 2017

54

1 reference

Europe PubMed Central

8 November 2017

877-887

1 reference

Europe PubMed Central

8 November 2017

8

1 reference

Europe PubMed Central

8 November 2017

Tyrosine-phosphorylated proteins: mediators of signal transduction from the tyrosine kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Growth factor signaling by receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Receptor protein-tyrosine kinases and their signal transduction pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

The current state of oncogenes and cancer: experimental approaches for analyzing oncogenetic events in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Cooperation between oncogenes

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Growth factors and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Oncogenes and signal transduction

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Signal transduction by receptors with tyrosine kinase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Cell-signaling targets for antitumour drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Signalling pathways as targets for anticancer drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Tyrosine kinase inhibition: an approach to drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Inhibition of cell signalling pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Overexpression of transforming growth factor alpha in psoriatic epidermis

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Transgenic mice provide new insights into the role of TGF-alpha during epidermal development and differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Signal transduction in atherosclerosis: integration of cytokines and the eicosanoid network

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

The restenosis paradigm revisited: an alternative proposal for cellular mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Inhibitors of protein tyrosine kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal gro

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site of the epidermal growth factor receptor in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Enantioselective inhibition of the epidermal growth factor receptor tyrosine kinase by 4-(alpha-phenethylamino)quinazolines

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Epidermal-growth-factor-dependent activation of the src-family kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Tyrosine kinase inhibitors. 7. 7-amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]pyrido[4,3-d]pyrimidines: a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Identification of heregulin, a specific activator of p185erbB2

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Purification of functionally active epidermal growth factor receptor protein using a competitive antagonist monoclonal antibody and competitive elution with epidermal growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Determination of inhibition constants, I50 values and the type of inhibition for enzyme-catalyzed reactions.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Structural and functional aspects of the multiplicity of Neu differentiation factors

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Heregulin induces tyrosine phosphorylation of HER4/p180erbB4

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

NDF/heregulin stimulates the phosphorylation of Her3/erbB3

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

The cellular response to neuregulins is governed by complex interactions of the erbB receptor family

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Expression of the ERBB3 gene product in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Receptor blockade with monoclonal antibodies as anti-cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Prolonged survival of mice with human gastric cancer treated with an anti-c-ErbB-2 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

Receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900242-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0006-2952(97)00242-6

1 reference

Europe PubMed Central

8 November 2017

1 reference

Europe PubMed Central

8 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42834569&oldid=1971536572"